The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing ...
The Food and Drug Administration has approved Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis, a chronic disease of the large ...
*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...
"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results